Form D · Biotechnology
Island Pharmaceuticals Ltd
Camberwell, C3 · CIK 0002012855
Offering snapshot reported Jun 5, 2024 · SEC filing
- Reported sold
- $1.22M Offering amount: $1.22M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 5, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 5, 2024 | Initial | $1,224,405 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $73.5K
- Finders' fees
- $0
- Form D file number
- 021-515176
Information in relation to total Offer, not USA only. Offer underwritten. To extent of the shortfall, underwriter and sub-underwriters subscribed for balance. 19 March 2024 company announcement. Total - $30,030.70 USD (0.6279 exch rate) from US residents
PAC Partners Pty Ltd received a 6% fee on the Gross amount raised under the offer, plus 4,500,000 options (0.6279 AUD-USD exchange rate)
Source: Form D, filed Jun 5, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Brookes | Director |
| David Foster | Director |
| Albert Hansen | Director |
| Paul Mac Leman | Director |
| Nick Mc Coy | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Suite 201, 697 Burke Road
Camberwell, C3, 3124
Camberwell, C3, 3124